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Abstract Much evidence supports a pivotal role for
inflammation in atherosclerosis. C-reactive protein (CRP),
the prototypic marker of inflammation in humans, is a
cardiovascular risk marker and may also promote athero-
genesis. CRP levels are increased in metabolic syndrome
and hypertension and confer increased risk of cardiovascu-
lar events in patients in these subgroups. Statins have been
shown to lower low-density lipoproteins and CRP indepen-
dently, and reduce cardiovascular events in subjects with
and without metabolic syndrome and hypertension. In this
review, we focus on the results from the primary prevention
statin trial, Justification for the Use of statins in Primary
prevention: an Intervention Trial Evaluating Rosuvastatin
(JUPITER), which showed reductions in LDL, CRP, and
cardiovascular events. Post-JUPITER, the new guidelines
will now need to consider recommending high-sensitivity
CRP testing to intermediate-risk metabolic syndrome
patients and those with hypertension and intermediate risk
so that we can better identify candidates at greater risk and
reduce cardiovascular burden in these subjects with statin
therapy.
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Introduction
Much evidence supports a pivotal role for inflammation in
all phases of atherosclerosis, from the initiation of the fatty
streak to the culmination in acute coronary syndromes [1,
2]. C-reactive protein (CRP) is the prototypic marker of
inflammation in humans.
High-Sensitivity CRP and Cardiovascular Risk
Numerousstudiesfromvariouspartsoftheworldhaveclearly
established that CRP predicts future risk for cardiovascular
disease (CVD) in apparently healthy persons, independent of
establishedriskfactorsinthemajorityofstudies.Inthestudies
to date, CRP has been shown to predict myocardial infarction
(MI), coronary artery disease (CAD) death, stroke, peripheral
arterial disease, and sudden death [3–5]. In the Women’s
Health Study, Ridker et al. [6] have shown that CRP is
additive to low-density lipoprotein (LDL) cholesterol and the
Framingham 10-year risk score in predicting future CVD in
healthy American women. Thus, based on these data, the
American Heart Association and Centers for Disease Control
and Prevention have issued a statement recommending that
CRP be used as a risk marker for CVD in individuals with a
Framingham risk score between 10% and 20% [3–5]. In their
recommendations, CRP levels <1 mg/L were considered
low-risk, 1 to 3 mg/L as average risk, and >3 mg/L as high
risk for CVD. Conditions that have been associated with
increased levels of CRP include adiposity, chronic inflam-
mation, metabolic syndrome, type 2 diabetes, hypertension,
chronic kidney disease, and sleep apnea [3–5].
CRP and Atherothrombosis
Although initial reports suggested a role of CRP as a
surrogate of the underlying inflammatory process of
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in vivo studies in clinical and experimental models strongly
points towards a role of CRP as a proatherogenic factor
(Table 1)[ 3–6, 7••].
CRP and Endothelial Function
An impressive amount of data now implicates CRP in
inducing endothelial cell activation and dysfunction [3–6,
7••, 8]. Earlier observations demonstrated that CRP levels
correlated inversely with endothelial vasoreactivity. The
most compelling data implicating CRP as a determinant of
endothelial dysfunction were studies demonstrating that
human CRP reduced basal and stimulated nitric oxide
release from arterial and venous endothelial cells [9, 10]. In
human aortic endothelial cells (HAEC), CRP resulted in
significant reduction in mRNA and protein for endothe-
lial nitric oxide synthase (eNOS). Furthermore, CRP
reduced eNOS activity (ie, conversion of L-arginine to
L-citrulline) and bioactivity (secretion of cyclic guano-
sine 5′-monophosphate [cGMP]), in part through de-
creasing eNOS mRNA stability [9, 10]. CRP mediates
uncoupling of eNOS via stimulation of NADPH oxidase
and inhibition of GTP cyclohydrolase [11].
Another important product of endothelial cells is
prostacyclin, a potent vasodilator, inhibitor of platelet
aggregation, and inhibitor of smooth muscle cell prolifer-
ation. CRP in concentrations as low as 10 μg/mL resulted
in a decrease in the release of the stable metabolite of
prostacyclin, prostaglandin F-1α (PGF-1 α) in both
human aortic and coronary artery endothelial cells, an
effect that was mediated through increased nitration of
prostacyclin synthase (PGIS) activity [12]. In addition,
CRP has a direct effect on fibrinolysis via effects on
increasing plasminogen activator inhibitor-1 (PAI-1) and
decreasing tissue plasminogen activator tPA [3–6, 7••, 8].
CRP activates Rho/Rho-kinase signaling, which in turn
activates NF-κB activity, resulting in increased PAI-1
expression [3–6, 7••, 8].
CRP and Monocytes
Cermak et al. [13] were the first to demonstrate that CRP
induced monocyte tissue factor (TF) secretion. Recently, we
demonstrated that intraperitoneal administration of CRP
(20 mg/kg) compared with human serum albumin (HuSA)
increased superoxide anion release and TF activity from
peritoneal macrophages in vivo (P<0.01) [14]. This was
confirmed using intrapouch administration of CRP (25 μg/
mL) compared with HuSA. In rat pouch macrophages in
vivo, we showed that CRP induced TF antigen and activity
was inhibited by inhibitors to NADPH oxidase. Further-
more, we demonstrated that inhibition of NF-κB activity
resulted in significant inhibition of CRP-induced TF
activity, and blockade of CD32 and CD64 reduced CRP-
induced TF. Several investigators have demonstrated that
CRP induces oxidative stress in vitro. We demonstrated that
lower concentrations of CRP (25 μg/mL) in vivo induce
superoxide anion release and that this is reversed by
inhibition of protein kinase C (PKC) and NADPH oxidase.
In rat pouch macrophages, we also demonstrated that the
effects of CRP on superoxide anion release were inhibited
via inhibition of ERK and c-Jun N-terminal kinase (JNK)
but not p38 MAPK [14]. These effects are abrogated by
blocking Fc receptors CD32 and CD64. Another important
in vivo demonstration we made is the induction of
myeloperoxidase activity in macrophages in vivo by human
CRP administration [15]. CRP also induces proinflamma-
tory cytokine release from human monocytes. A single
report has shown increased CD11b expression on mono-
cytes incubated with CRP, accompanied by increased
adhesion of these monocytes to LPS-activated human
umbilical vein endothelial cells [3–6, 7••, 8]. We have
shown that CRP increases monocyte-endothelial cell
adhesion under shear stress and static conditions via
increased NF-κB and increasedintercellular adhesionmolecule
1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1)
expression [3–6, 7••, 8]. We have also recently shown that
CRP promotes macrophage colony-stimulating factor (M-
Table 1 Proatherogenic effects of C-reactive protein
Endothelium Monocytes
Increased VCAM, ICAM-1, E-selectin, MCP-1, monocyte adhesion Increased tissue factor
Increased PAI-1, IL-8, CD40/CD40L, MMP-1, ET-1 Increased M-CSF and proliferation
Decreased eNOS, prostacyclin, tPA, promotes endothelial dysfunction Increased superoxide and myeloperoxidase
Increased proinflammatory cytokines Decreased IL-10
Impaired EPC number and function in vitro Promotes oxLDL uptake and decreases cholesterol efflux
eNOS endothelial nitric oxide synthase, EPC endothelial progenitor cells, ET endothelin, ICAM intercellular adhesion molecule, IL interleukin,
MCP monocyte chemotactic protein, M-CSF macrophage colony-stimulating factor, MMP matrix metalloproteinase, oxLDL oxidized low-density
lipoprotein, PAI plasminogen activator inhibitor, tPA tissue plasminogen activator, VCAM vascular cell adhesion molecule
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phage proliferation; this effect appears to be mediated via NF-
κB activation and through the Fc receptors CD32 and CD64
[16]. In addition, we have demonstrated that in vivo
administration of CRP promotes uptake of oxidized LDL
(oxLDL) and intracellular cholesterol ester accumulation in rat
macrophages in vivo [17]. The increased uptakeofoxLDL by
CRP was inhibited by pretreatment with antibodies to CD32,
CD64, CD36, and fucoidin, suggesting uptake by both
scavenger receptors and Fc receptor. Thus, it is clear that
CRP is proatherogenic in monocyte-macrophages. Further-
more,CRPispresentinfoamcellsintheatheroscleroticlesion
and activates complement [3–6, 7••, 8].
CRP Promotes Atherothrombosis: Studies in Rats
and Transgenic Mice
Additional evidence for an in vivo role of CRP in CVD
stems from studies demonstrating the ability of CRP to
induce MI in a rat coronary ligation model. These studies
showed increase cerebral infarct size in rats following
middle cerebral artery occlusion, and promotion of neo-
intimal formation after balloon angioplasty [3–6, 7••, 8].
In the CRP transgenic mice, Danenberg et al. [18]
showed that compared to wild-type mice in which CRP levels
are undetectable, CRP levels increased to 18±6 mg/L.
Following injury to the femoral artery, there was complete
thrombotic occlusion in the femoral artery in 75% of the
human CRP transgenic mice when compared to 17% of the
wild-type mice at 28 days (P<0.05). Furthermore, arterial
photochemical injury to the carotids shortened clot formation
time in the human CRP transgenic mice compared to the
wild-type mice. Although the human CRP transgene resulted
in increased atherosclerotic lesion on an apolipoprotein E
(apoE)-knockout background, it should be pointed out that
the effect was only seen in male mice and was modest,
questioning the validity of the mouse model. In two
recent studies, transgenic expression of human CRP had
no effect on development, progression, or severity of
spontaneous atherosclerosis, or on morbidity or mortality,
in male apoE-deficient C57BL/6 mice up to 56 weeks,
despite deposition of human CRP and mouse comple-
ment component 3 in the plaques; again, there was no
effect on atherosclerosis in the apoE*3-Leiden (E3L)
transgenic mice carrying the human CRP gene [3–6, 7••,
8] .A l s o ,P e p y se ta l .[ 19] have shown that a small
molecule inhibitor (bis phosphatidylcholine) prevents the
increase in infarct size following coronary ligation.
These studies indicate that CRP is not only a risk marker
but may indeed promote atherogenesis. Two conditions
where CRP levels are high are the metabolic syndrome
(MetS) and hypertension, and high levels of CRP predict
increased risk in these individuals [20].
Metabolic Syndrome
The metabolic syndrome (MetS) comprises a cluster of
abnormalities, with insulin resistance (IR) and adiposity as
central features [21]. Five diagnostic criteria have been
identified by the National Cholesterol Education Program
Adult Treatment Panel III (NCEP-ATP III), and the
presence of any three features (central obesity, dyslipidemia
[high triglycerides, low HDL], hypertension, and impaired
fasting glucose) is considered sufficient to diagnose the
syndrome. Approximately 35% of US adults have the
MetS, and the prevalence increases with age [22]. MetS
confers a two to fourfold increased risk for CVD [23] and
fivefold increased risk of diabetes [23]. Low-grade chronic
inflammation is a central feature of MetS and could
contribute to increased risks of both CVD and diabetes in
MetS. Circulating levels of several inflammatory molecules
have been measured to assess their value in predicting
CVD. The best characterized and well-standardized marker
of these is CRP. Numerous studies have now confirmed that
CRP levels are elevated in individuals with the MetS.
Furthermore, it has been proposed that high-sensitivity CRP
(hsCRP) be added as a clinical criterion for MetS and for
creation of an hsCRP-modified CHD risk score [24].
Elevated hsCRP Levels and Increased Cardiovascular Risk
in MetS
Evidence supporting the hypothesis that elevated CRP
levels contribute to increased cardiovascular risk is now
available from at least six major prospective studies. These
studies include the Physicians Health Study (PHS), Women’s
Health Study (WHS), Atherosclerosis Risk in Communities
(ARIC), Air Force/Texas Coronary Atherosclerosis Preven-
tion Study (AFCAPS/TexCAPS) in the United States and the
Monitoring Trends and Determinants in Cardiovascular
Disease (MONICA) and Reykjavik studies from Europe [20,
23, 25]. Additionally, with regards to MetS, Yudkin et al.
[26], in 107 non-diabetic subjects, conducted Z-score
analyses and found a very significant correlation between
inflammatory markers and several features of the MetS. CRP
levels were shown to be strongly associated with insulin
resistance calculated from the homeostatic model assessment
(HOMA), blood pressure, low high-density lipoprotein
(HDL), triglycerides, and to levels of the proinflammatory
cytokines interleukin-6 (IL-6) and tumor necrosis factor
(TNF). Body mass index (BMI) and insulin resistance were
the strongest determinants of the inflammatory state. There is
a linear relationship between the number of metabolic
features and increasing levels of hsCRP. Furthermore, Festa
et al. [27] from Insulin Resistance and Atherosclerosis Study
(IRAS), showed that hsCRP was positively correlated with
BMI), waist circumference, blood pressure, triglycerides,
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insulin, and it was inversely correlated with HDL cholesterol
and insulin sensitivity index. The strongest associations are
observed between CRP levels, central adiposity, and insulin
resistance. The largest study to date that examined the
association between inflammation and the MetS was the
Third National Health and Nutrition Examination Survey
(NHANES) study [20, 23, 25]. In a representative sample of
the US population (8570 participants >20 years of age),
subjects with the MetS, defined using ATP III criteria, were
more likely than those without the syndrome to have
elevated levels of markers of inflammation such as CRP,
fibrinogen, and leukocyte count. Thus, there appears to be a
clear relationship between the numbers of metabolic features
and increasing hsCRP levels. In addition, we have shown
that CRP levels were equivalent to the ratio of high–
molecular weight (HMW) adiponectin to CRP in predicting
MetS using receiver-operating characteristic (ROC) analyses
[20, 23, 25]. Thus, MetS is a proinflammatory state
characterized by increased CRP levels.
Ridker et al. [6], in a large-scale population cohort of the
Women’s Health Study, evaluated the potential inter-
relationships between CRP, the MetS, and incident cardio-
vascular events. In the 8-year prospective follow-up of
14,719 women in the WHS, an hsCRP of >3 mg/L in
patients with MetS predicted a greater age-adjusted relative
risk for future cardiovascular events. Furthermore, they
reported that at all levels of severity of the MetS, CRP
added prognostic information with regard to subsequent
risk of incident CVE and was additive to the Framing-
ham Risk Score. Thus, it has been proposed that hsCRP
be added as a clinical criterion for MetS and for creation
of an hsCRP-modified coronary heart disease (CHD) risk
score [24].
In the West of Scotland Coronary Prevention Study
(WOSCOPS), in which 6447 men were followed for
4.9 years, an hsCRP level >3 mg/L predicted greater
cardiovascular risk in patients with the MetS in a
multivariate model [20, 23]. In the Framingham Offspring
Study [23, 25], both CRP and MetS were independent
predictors of new cardiovascular events but were not
additive. In an Italian study, patients with MetS and CRP
>3 mg/L had higher incidence of both carotid and coronary
artery disease [20, 23, 25]. It was demonstrated in the
Nurses’ Health Study and Health Professionals Follow-up
Study (HPS) that although MetS was a strong predictor of
CHD in both men and women, CRP was additive in men
only [23, 25]. In a smaller Japanese Study of 461 patients
with acute MI, CRP levels were additive to MetS in
predicting future major adverse cardiac events (MACE)
[23, 25]. Collectively, all these studies support the
hypothesis that increased CRP in the setting of MetS
confers an increased risk of future cardiovascular events.
Additionally, a genome-wide association study has been
performed recently among 6345 apparently healthy women
in which 336,108 single nucleotide polymorphisms (SNPs)
were evaluated as potential determinants of plasma CRP
concentration [23, 25]. Overall, seven loci that associate
with plasma CRP at levels achieving genome-wide statis-
tical significance were found. Two of these loci (GCKR and
HNF1A) are suspected or known to be associated with
maturity-onset diabetes of the young, one is a gene-desert
region on 12q23.2, and the remaining four loci are in or
near the leptin receptor protein gene, the apoE gene, the IL-
6 receptor protein gene, or the CRP gene itself. The protein
products of six of these seven loci are directly involved in
MetS, insulin resistance, beta-cell function, weight homeo-
stasis, and/or premature atherothrombosis. Thus, it is
concluded that common variation in several genes involved
in metabolic and inflammatory regulation have significant
effects on CRP levels, consistent with CRP’s identification
as a useful biomarker of risk for incident vascular disease
and diabetes. Overall, it appears that in individuals with
MetS, an elevated CRP confers a greater risk for cardio-
vascular events by its action on vascular cells, such as
activation of monocytes and induction of endothelial cell
dysfunction.
Statins and CRP
Several large clinical trials have demonstrated that statins
(3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA]
reductase inhibitors) decrease the incidence of cardiovas-
cular events in both primary and secondary prevention [23,
25]. In these trials, statin therapy resulted in significant
reduction in LDL cholesterol and it has been generally
assumed that cholesterol reduction by statins is the
predominant mechanism for the reduction in cardiovascular
events. However, subgroup analyses of large clinical trials,
such as WOSCOPS, Cholesterol and Recurrent Events
(CARE), and HPS, have suggested that the beneficial
effects of statins may extend to mechanisms beyond
cholesterol reduction. Further evidence in support of the
pleiotropic effects of statins is provided by angiographic
trials that have demonstrated clinical improvements with
statins far exceeding changes in the size of the atheroscle-
rotic lesions. The Myocardial Ischemia Reduction with
Acute Cholesterol Lowering (MIRACL) trial also demon-
strated that statins were effective in reducing recurrent
ischemic events in as soon as 16 weeks after an acute
coronary event [25, 28]. Although serum cholesterol was
reduced 40%, this time frame was probably too short for
changes in vascular remodeling. In addition, in the
Pravastatin or Atorvastatin Evaluation and Infection Ther-
apy (PROVE-IT) study, individuals with hsCRP levels
34 Curr Atheroscler Rep (2011) 13:31–42<2 mg/L and LDL cholesterol >1.8 mmol/L (70 mg/dL)
after statin therapy had cardiovascular event rates similar to
those in individuals with LDL cholesterol <1.8 mmol/L
(70 mg/dL) but hsCRP >2 mg/L after statin therapy [25,
28]. This suggests that lower inflammatory status confers as
much protection as lower cholesterol levels in patients with
acute coronary syndrome. Similarly, in the Reversal of
Atherosclerosis with Aggressive Lipid Lowering (REVER-
SAL) trial, the benefits of atorvastatin in terms of reducing
C-reactive protein levels and total atheroma volume in the
coronary arteries exceeded those of pravastatin, even at
similar cholesterol reductions, arguing for the pleiotropic
effects of statins [23, 27]. The clinical benefit of statin
drugs used in these studies is manifest early in the course of
lipid-lowering therapy well before plaque regression could
occur, pointing to the pleiotropic effects of statins. Several
prospective clinical trials have shown that statins lower
hsCRP levels, and this effect appears to be independent of
its effects on lipid lowering. Furthermore, we have shown
that this is a class effect because simvastatin, pravastatin,
and atorvastatin, at equivalent LDL cholesterol–lowering
doses, significantly reduced hsCRP levels in patients with
hyperlipidemia [29].
Statins, CRP, and MetS
Although several studies have shown beneficial pleiotropic
effects of statins on lowering hsCRP, lowering other
biomarkers of inflammation, and improving endothelial
function [25, 28] (all of which may be important in
reducing cardiovascular risk in MetS patients), very few
clinical trials have examined the effects of the statins on
cardiovascular events in patients with MetS (Table 2).
In the Scandinavian Simvastatin Survival Study (4S),
subgroup analysis was performed on 3933 nondiabetic
patients with clinically established CHD, serum total
cholesterol level of 5.5 to 8.0 mmol/L, and serum
triglyceride level ≤2.5 mmol/L [23, 24]. Endpoints were
total mortality, coronary mortality, major CHD event,
myocardial revascularization, any CHD event, stroke, and
any atherosclerotic event. Over the 5.4-year median follow-
up period, simvastatin therapy produced similar significant
reduction in serum lipid levels in 893 patients with MetS
(23% of the nondiabetic subjects) and in 3040 patients
without MetS. The relative risks (RR) of main endpoints in
simvastatin-treated patients compared with placebo-treated
patients with MetS were as follows: total mortality 0.54
(95% CI, 0.36–0.82), coronary mortality 0.39 (0.23–0.65),
major CHD event 0.59 (0.45–0.77), and any atherosclerotic
event 0.69 (0.56–0.84). The corresponding RRs in patients
without MetS were 0.72 (0.56–0.91), 0.62 (0.45–0.84),
0.71 (0.61–0 . 8 2 ) ,a n d0 . 7 6( 0 . 6 8 –0.85). These studies
showed that simvastatin resulted in substantial relative
reduction in the risk of cardiovascular events in nondiabetic
heart disease patients with or without MetS; however, the
absolute benefit may be greater in patients with MetS
because they are at a higher absolute risk.
In lower-risk primary prevention patients with and
without MetS, lovastatin therapy in the AFCAPS/TexCAPS
study also resulted in a similar significant reduction in
major coronary events [25, 28]. Indeed, in this study, it
appeared that in those subjects that did not meet NCEP-
ATP III criteria for treatment with a lipid-lowering agent,
the benefit of statin therapy in reducing coronary events in
MetSpatientswasonlyevidentinthosewithCRP>1mg/L.In
subjects with CRP <1 mg/L, regardless of the presence of
MetS, there was no benefit of statin therapy. Thus, in
primary prevention in low-risk subjects, CRP may be an
effective criterion to use to determine if statin therapy is
warranted in subjects with MetS. The WOSCOPS was
another primary prevention study which showed similar
significant reduction in major coronary events in patients
with and without MetS [23, 24].
A subanalysis of the Treating to New Targets (TNT) trial
evaluated whether aggressive lowering of LDL cholesterol
with high-dose atorvastatin provides superior cardiovascu-
lar benefit for patients with both heart disease and MetS
compared to regular-dose atorvastatin [25, 28]. In this
subanalysis, there were 5584 MetS patients who were
Table 2 Statin trials and metabolic syndrome
Study Statin Endpoint
4S (secondary prevention Simvastatin Significant reduction in CVE in MetS
AFCAPS/TexCAPS (primary prevention) Lovastatin Significant benefit with hsCRP >1 mg/L
WOSCOPS (primary prevention) Simvastatin Significant reduction in coronary events in MetS
TNT (secondary prevention) Atorvastatin Significant reduction in CVE in MetS with high-dose statin
JUPITER (primary prevention) Rosuvastatin Significant reduction in CVE, especially in those who achieved
hsCRP <2 mg/L with statin
CVE cardiovascular events, hsCRP high-sensitivity C-reactive protein, MetS metabolic syndrome
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high-dose atorvastatin (80 mg/d; n=2764). The primary
endpoint included the time to first major cardiovascular
event (defined as death from CHD, nonfatal nonprocedure-
related MI, resuscitated cardiac arrest, or fatal or nonfatal
stroke). In the patients with heart disease and MetS, mean
on-treatment LDL cholesterol concentrations at 3 months
were 99.3 mg/dL with low-dose atorvastatin and 72.6 mg/dL
with high-dose atorvastatin. At a median follow-up of
4.9 years, major cardiovascular events occurred in 13% of
patients receiving 10 mg/d atorvastatin compared with 9.5%
ofthosereceiving80mg/dofatorvastatin(hazardratio[HR]=
0.71; 95% CI, 0.61–0.84; P<0.0001). Irrespective of treat-
ment assignment, significantly more patients with MetS
(11.3%) had a major cardiovascular event than those without
MetS (8.0%; HR=1.44; 95% CI, 1.26–1.64; P<0.0001).
This increased risk was significantly reduced by 29% in
those on intensive therapy with high-dose atorvastatin
beyond that achieved with regular-dose atorvastatin in the
subgroup of MetS patients without diabetes, whereas only
8.2% persons receiving 80 mg/d of atorvastatin had a
primary event, a much larger number (ie, 11.6%
receiving10 mg/d of atorvastatin) experienced the primary
event. These findings represent a 30% relative reduction in
the risk of a major cardiovascular event in favor of the high-
dose atorvastatin subset (relative risk of 0.70; 95% CI, 0.57–
0.84; P=0.0002). These results argue for aggressive treat-
ment of heart disease patients with MetS with high-dose
statin therapy, which was also safe. However, this study
failed to study subjects with MetS alone without heart
disease, and thus it is unclear if these results can be
extrapolated to MetS subjects without heart disease.
Furthermore, because all of these trials were post hoc
analyses, abdominal obesity was not examined with the
accepted measure of the waist circumferences, instead a
BMI >28 to 30 kg/m
2 was used. Also, the different trials
used different definitions of the MetS, especially with
regards to the cut-offs of fasting glucose. Thus, future statin
trials in MetS subjects should assess the effects of statin
therapy on all features of the MetS as identified by the
modified NCEP-ATP III criteria.
The JUPITER Trial, CRP, and MetS
The Justification for the Use of statins in Primary
prevention: an Intervention Trial Evaluating Rosuvastatin
(JUPITER) trial addressed the hypothesis that men and
women without overt CVD, with an LDL cholesterol below
the current threshold for treatment, an elevated CRP would
benefit from statin therapy. JUPITER enrolled 17,802
apparently healthy middle-aged men (≥50 years) and
women (≥60 years) from 1315 sites in 26 countries.
Patients were free of diabetes and heart disease, with
normal LDL levels (<130 mg/dL) but high hsCRP levels
(≥2.0 mg/L [median of 4.2 mg/L]). Participants were
randomly assigned to either 20 mg/d of rosuvastatin or
placebo. Enrollees were followed for a primary composite
endpoint of MI, hospitalization for unstable angina, heart-
related death, arterial revascularization, or stroke. Although
planned as a 4-year study, the trial was stopped after a
median follow-up time of 1.9 years based upon advice from
an independent monitoring board and study steering
committee [30, 31••].
Rosuvastatin (20 mg/d) lowered CRP levels by 37%
(down to a 12-month mean of 2.2 mg/L), lowered LDL by
50% (down to a 12-month mean of 55 mg/dL), and sharply
decreased the number of cardiovascular events and all-
cause mortality. At the end of 1.9 years, rosuvastatin
therapy significantly lowered the primary composite end-
point by 44% compared with placebo. In particular, there
was a 55% lowering of nonfatal MI, 48% fall in the risk of
nonfatal stroke, and a 47% fall in the risk of serious cardiac
events [30, 31••]. The reduction in vascular risk was greater
in JUPITER than in previous statin trials. Furthermore, it
was later shown that absolute risk reductions associated
with rosuvastatin treatment were greater among those
≥70 years of age than among the younger group. For the
primary endpoint, there was an event rate reduction of 0.77
versus 0.52 per 100 person-years in the older versus
younger group. This would mean one-third fewer people
needing treatment to prevent an event over 5 years, at a
number-needed-to-treat (NNT) of 19 in the elderly group
versus 29 in the younger group.
In the subgroup of MetS subjects (41% of subjects),
there was a similar significant benefit as in those without
MetS. Furthermore, in subjects who achieved on treatment
LDL <1.8 mmol/L and hsCRP <2 mg/L, the reduction in
events was significantly greater (65% reduction). In this
trial, it is important to note that in the rosuvastatin group,
achieved hsCRP levels were predictive of event rates,
irrespective of the target LDL or apoB to apoA-1 ratio [30,
31••]. These data indicate that in subjects with and without
MetS, reduction in events with statin therapy can be
monitored by reductions in both LDL cholesterol and
hsCRP.
The recent Canadian primary prevention guidelines
endorse the use of statin therapy among individuals at
intermediate risk who have elevated levels of hsCRP [32••].
In JUPITER, 6091 participants (2525 women and 3566 men)
had baseline estimated 10-year Framingham risks of 5% to
10%, and 7340 participants (1404 women and 5936 men) had
baseline estimated Framingham risk of 11% to 20%. In these
two subgroups, relative risk reductions consistent with the
overall trial treatment effect were observed (HR=0.55; 95%
CI, 0.36–0.84; 5-year NNT=40; P=0.005 for those with 5%
36 Curr Atheroscler Rep (2011) 13:31–42to 10% risk; hazard ratio=0.51; 95% CI, 0.39–0.68; 5-year
NNT=18; P<0.0001 for those with 11% to 20% risk).
Consistent with recent evidence-based Canadian Cardiovas-
cular Society guidelines for primary prevention, the JUPI-
TER trial demonstrated that 20 mg/d of rosuvastatin
significantly reduces major cardiovascular events among
men and women with elevated hsCRP and intermediate
(10% to 19%) 10-year risk.
Summary of Statin Therapy in MetS
JUPITER will undoubtedly change the way primary
prevention patients with low cholesterol levels are treated.
If data from the placebo group in the JUPITER trial are
extrapolated over 10 years, the 10-year risk of CHD events
(MI and cardiovascular death) in the placebo group is about
6%. For patients with a Framingham risk score of 10% to
20%, the updated ATP III guidelines from 2004 recommend
an LDL goal of <130 mg/dL with an optional goal of
<100 mg/dL. However, for patients with cardiovascular risk
factors and Framingham risk score <10%, ATP III
recommends considering pharmacologic therapy only if
the LDL is >160 mg/dL. Although rosuvastatin was clearly
beneficial in the JUPITER population, most of the patients
in the JUPITER study would not have received statin
therapy according to the current ATP III guidelines. Given
the benefits of statin therapy seen in JUPITER, it would be
reasonable to measure hsCRP levels in asymptomatic
women 50 years and older and asymptomatic men 60 years
and older with MetS in whom the decision to treat with
statin therapy is unclear and to consider statin therapy for
those with elevated hsCRP levels (>2 mg/L). Also, it would
be prudent to initiate statin therapy in individuals at
intermediate risk (10%-19% Framingham risk score) with
elevated levels of hsCRP.
Statin Therapy in Hypertension
Cardiovascular risk factors frequently occur together, and
their combined unfavorable effects are generally greater
than the sum of their individual components. In the MetS,
hypertension frequently co-exists with dyslipidemia, obesi-
ty, and abnormalities of glucose metabolism (particularly
insulin resistance). Indeed, hypertension and dyslipidemia
are the most important cardiovascular risk factors in
patients for both the primary and secondary prevention of
CVD, and these risk factors occur together more than 50%
of the time [33]. A recent analysis of NHANES 2003–2004
showed that the prevalence of hypertension ranged from
23.1% in those without CVD to 51.8% to 81.1% in those
with cardiovascular co-morbidities (chronic kidney disease
81.1%; diabetes 76.8%; peripheral artery disease 73.7%;
coronary artery disease 73.0%; congestive heart failure
71.4%; stroke 69%; metabolic syndrome 61.5%; dyslipide-
mia 51.8%) [34].
The large benefit achieved in decreasing cardiovascular
events with statin treatment in patients with a wide range of
cholesterol levels cannot be attributed to only their
cholesterol-lowering effects. This conclusion is based partly
on the rapidity of the decrease in cardiovascular events after
statin initiation. The benefits of these effects, independent
of their lipid-lowering actions, have been referred to as the
pleiotropic effects of statins. Some of these effects include
modification of the toxic effects of circulating LDL
cholesterol on vascular endothelium, vascular smooth
muscle cell hypertrophy and proliferation, and fibrin
deposition [35].
Statins, Endothelium and Hypertension
The vascular endothelium is a dynamic endocrine structure
that regulates contractile, secretory, and mitogenic activities
in the vessel wall [36]. It also affects hemostatic processes
within the vascular lumen. Endothelial dysfunction is
present in patients with a variety of cardiovascular risk
factors, including hypertension, diabetes mellitus, dyslipi-
demia, and abnormalities of glucose metabolism. Statin
therapy may have a beneficial effect on endothelial
dysfunction. Statins may restore endothelial function by
increasing the bioavailability of nitric oxide (NO), reducing
oxidative stress, and inhibiting inflammatory responses
[36]. Of interest, statins exhibit their effects on vascular
endothelium quite early, generally within 24 h in the course
of treatment. This may be mediated by the effect of statins
on NO and the reduction of oxidative stress [37].
Epidemiology and Pathophysiology
Hypertension and dyslipidemia are frequently thought of as
different risk factors, but they are both associated with
markers of inflammation and oxidative stress that point to a
common metabolic pathway resulting in the problems
associated with these disorders. Epidemiologic studies have
demonstrated that the presence of familial combined
hyperlipidemia was increased 10-fold in individuals with
essential hypertension [38]. Metabolic abnormalities (eg,
dyslipidemia and insulin resistance) are associated with
increased risk for the subsequent development of hyperten-
sion. These frequently co-exist in individuals to a higher
degree than expected based upon their individual preva-
lence. Additionally, multiple abnormalities that predispose
to the development of hypertension are demonstrated in the
normotensive children of hypertensive adults. In the
Genetic Epidemiology Network of Arteriopathy (GENOA)
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was found in hypertensive patients [39]. In addition to NO,
endothelial vasoreactivity is dependent on a number of
other molecules. Inhibition of the production of potent
endothelial-derived vasoconstrictors such as endothelin
(ET-1) results in improvement of blood flow. Statins
have been shown to decrease the expression of ET-1,
mRNA, and ET-1 synthesis in bovine aortic endothelial
cells in vitro [40].
The vascular renin-angiotensin-aldosterone system
(RAAS) is involved in the early stages of endothelial
dysfunction and inflammation, and is important in the
development of hypertension. It may also promote a
cascade of cellular and molecular events leading to the
formation of atherosclerosis and plaque instability. In-
creased cholesterol is also associated with an over-
expression of angiotensin II type one receptors in experi-
mental models as well as in humans [41]. This may lead to
an increase of angiotensin II-induced blood pressure
elevation [36, 41]. There is some evidence that statins
may partly restore the increased sensitivity to angiotensin II
in healthy young adults with isolated elevated cholesterol
and down-regulate AT-1 receptor expression. In a rat model,
it was found that dietary lipids may affect sodium handling
and the development of hypertension. Cholesterol may
decrease sodium efflux along the nephron, resulting in a
reduction in the fractional clearance of sodium and favoring
in its retention. Interestingly, atorvastatin has been reported
to increase the urinary secretion of sodium in conjunction
with an increase in renal secretion of uric acid.
As noted above, hypertension and dyslipidemia are both
characterized by increased levels of circulating markers of
inflammation and oxidative stress. Hypertension induces
endothelial dysfunction by a variety of mechanisms in
addition to inflammation and oxidative stress. Structural
alterations of the vasculature may occur following exposure
to sheering forces with elevated blood pressure, with
resulting progressive deposition of collagen within the
vascular wall. This deposition of collagen may result in
physiologic abnormalities of the wall, with increased
vascular stiffness and reduction in compliance. In addition,
the induced structural alterations in the vessels may result
in pathologic alterations in vascular physiology. Hyperten-
sive endothelial dysfunction may result in the release of NO
coupled with the resulting decrease in the capacity for
vasodilation.
CRP and Hypertension
As noted above, inflammation is felt to have a major role in
the development of hypertension. In this regard, CRP levels
have been shown to be associated with hypertension [42].
Elevated CRP may contribute to endothelial dysfunction by
reducing the production of NO, resulting in vasoconstric-
tion. Additionally or alternatively, CRP may be a proather-
osclerotic factor. In one study, it was found that an elevated
CRP value preceded new-onset hypertension at an early
stage among an elderly healthy population [43]. Alterna-
tively, elevated blood pressure could induce a vascular
inflammatory state, resulting in an elevated CRP [44].
Regardless of whether an elevated CRP is a cause or an
effect of hypertension, the association between an elevated
CRP and cardiovascular disease is clear. In the WHS, CRP
was found to be a strong independent predictor of the
development of hypertension [6, 24]. Analysis of 15,215
healthy women over the age of 45 years found a step-wise
association between blood pressure levels and median
levels of CRP; this step-wise association was noted for
both systolic and diastolic blood pressure. In risk factor–
adjusted models, controlling for other cardiovascular risk
factors, women with blood pressure <120 / <75 mm Hg had
a mean level CRP of 1.33 mg/L in comparison to women
with blood pressure ≥160 / ≥95 mm Hg, who had a mean
CRP level of 1.84 mg/L. Both CRP and blood pressure
were strong independent predictors of future cardiovascular
events. Those individuals with CRP levels in the top
quartile had a twofold increased risk of developing elevated
blood pressure compared to those with the CRP levels in
the lowest quartile. Additional analysis showed that among
women with either high or low blood pressure, survival was
worse if CRP level were elevated ≥3 mg/L.
There are several possible mechanisms by which CRP
levels may cause increasing blood pressure. Hypertension
may directly promote inflammation of blood vessels.
Subjects with elevated blood pressure demonstrate in-
creased production of reactive oxygen species as well as
increased oxidative stress. CRP may also decrease NO
production by endothelial cells [8–11]. In hypertensive
patients, elevated CRP levels are associated with arterial
stiffness. Increased vessel stiffness has been found to be a
predictor of elevated blood pressure in normotensive
offspring of hypertensive individuals. Aortic stiffness has
also been shown to be a strong independent predictor of
cardiovascular illness in hypertensive patients. In summary,
by increasing ET-1 and IL-6 and reducing NO production,
CRP may change the vascular system toward a proinflam-
matory and vasoconstrictive state with increased arterial
stiffness, resulting in hypertension [8–11].
Effect of Statins on Blood Pressure Levels
The evidence for the blood pressure–lowering effects of
statins in humans has been mixed, but the preponderance of
data indicates that there is a reduction of blood pressure
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statin therapy on blood pressure is generally modest, with
reduction in systolic blood pressure of 3 to 5 mm Hg and
diastolic blood pressure of 1 to 3 mm Hg. The effect of
statins on blood pressure appears to be most pronounced in
individuals with higher and more difficult to control
hypertension.
In the Brisighella Heart Study, 1356 hypercholesterol-
emic individuals were randomly assigned to a low-fat diet,
cholestyramine, gemfibrozil, or simvastatin for five years.
Participants were divided into four quartiles according to
systolic blood pressure. A significant decrease in blood
pressure was noted in the two upper quartiles of systolic
blood pressure and was greater in those treated with lipid-
lowering drugs. Notably, the blood pressure reduction was
greatest in patients treated with simvastatin despite a
comparative reduction in LDL cholesterol [45].
A meta-analysis of all studies that reported blood
pressure data during statin treatment included 20 random-
ized controlled trials and 828 patients [46]. Treatment with
statins during the studies ranged from 1 to 12 months.
Systolic blood pressure was significantly lower in patients
treated with statins than in patients on placebo or on
another lipid-lowering medication. The average decrease of
1.9 mm Hg was modest. However, the effect on blood
pressure was more pronounced when the analysis was
restricted to studies with a baseline blood pressure of
>130 mm Hg. Here, the average change is systolic blood
pressure was 4.0 mm Hg. Diastolic blood pressure was also
lowered on average by 0.9 mm Hg in all studies but by
1.2 mm Hg in studies with patients with a diastolic blood
pressure of >80 mm Hg.
The benefit of lowering blood pressure and cholesterol
was evaluated in the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT) [47].
One arm of ALLHAT was designed to determine whether
pravastatin, compared with usually care, would reduce all-
cause mortality in 10,355 patients with hypertension and
moderate hypercholesterolemia along with at least one
other CHD risk factor. All-cause mortality was similar
between the 40-mg/d pravastatin group and the usual-care
group. These results could be attributed to the small
differences in total cholesterol (9.6%) and LDL cholesterol
(16.7%) between the two groups.
In the Anglo-Scandinavian Cardiac Outcomes Trial–
Lipid Lowering Arm (ASCOT-LLA) trial, extra antihyper-
tensive drug use in the placebo group may have obscured
the atorvastatin blood pressure–lowering effect [48]. In this
study, 19,342 men and women with hypertension and at
least three other cardiac risk factors were randomized to
different antihypertensive drug groups. A total of 10,305 of
these patients with normal or slightly elevated total
cholesterol were randomized to atorvastatin (10 mg/day)
or placebo. The atorvastatin arm was stopped prematurely
at 3.3 years because of a significant reduction in the
primary endpoint (−36%; P=0.005). In addition to the
benefit on total cholesterol and LDL-C, the atorvastatin
group had a decrease in blood pressure at 18 months of
0.7 mm Hg.
A cross-sectional study of 2584 hypertensive patients
with no known CVD from the NHANES 1999 to 2002
compared people not receiving a statin medication with
those who were [49]. Significantly more statin users had
blood pressure <140/90 mm Hg (52.2% vs 38.0%), but
these individuals were also more likely to comply with a
low-salt diet use, use antihypertensive medication, and be
nonsmokers. The Plaque Hypertension Lipid Lowering
Italian study (PHYLLIS) was the largest study using office
determination of blood pressure and included 508 hyper-
tensive hypercholesterolemic patients treated with hydro-
chlorothiazide or fosinopril for 2.6 years. There was no
additional effect on blood pressure when pravastatin
(20 mg/d) was added.
Results of studies of statins on blood pressure during
ambulatory blood pressure monitoring (ABPM) have
generally found that there is a modest reduction of blood
pressure with the use of statins. In one study in hyperten-
sive patients with elevated cholesterol, statin therapy
resulted in a non-significant tendency to reduce casual
systolic and diastolic blood pressures, but average daytime
systolic and diastolic blood pressures dropped significantly
[50]. There was not a significant change in night time blood
pressure or in circadian blood pressure profiles. In another
study that compared the effects of adding atorvastatin or
diet to antihypertensive agents in hypertensive hypercho-
lesterolemic patients, there was a reduction in systolic and
diastolic blood pressures with the statin. Adding a moderate
dose of atorvastatin to antihypertensive agents in hyper-
cholesterolemic patients with resistant hypertension
resulted in a significant reduction in systolic and diastolic
blood pressures than that found with a change in diet alone.
The results of statins on ABPM have not always yielded
blood pressuring–lowering effects. In a study comparing
the effects of valsartan alone with valsartan plus simvastatin
on 24-hour APBM, there was no difference between the
two experimental groups.
There are a number of difficulties in the clinical trial
assessment of the antihypertensive effects of statins. In
many of the clinical trials described above, the effect of
statins on blood pressure was not the primary endpoint of
the trial. Patient populations have been heterogeneous,
including dyslipidemic patients in studies of both normo-
tensive and hypertensive subjects. Thus, the effect of statins
on blood pressure could have been masked by other
antihypertensive medications given to some of the subjects.
In many of the studies, different hypertensive drugs were
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Antihypertensive medications have different pharmacologic
effects, including differential effects on endothelial func-
tion. This could lead to different interactions with statin
therapy in terms of blood pressure lowering effects.
In JUPITER, 10,208 of the total 17,802 patients had
hypertension. Rosuvastatin therapy significantly decreased
the primary endpoint of nonfatal MI, stroke, revasculariza-
tion, angina, and CVD death similarly in those with and
without hypertension, with a concomitant reduction in LDL
cholesterol and hsCRP levels [30, 31••].
In addition, hypertension results in chronic kidney
disease (CKD). In the post hoc analyses of JUPITER in
those with moderate CKD, rosuvastatin was associated with
a significant 45% reduction in MI, angina, stroke, CVD
death, and a 44% reduction in all-cause mortality [51••].
LDL and hsCRP reductions were similar in those with and
without CKD. Furthermore, median estimated glomerular
filtration rate (eGFR) improved in those that received
rosuvastatin compared to placebo.
Summary of Statin Therapy in Hypertension
Statins appear to exert a modest, but clinically relevant,
antihypertensive effect. However, their benefit in hyperten-
sive patients is considerably beyond that which would be
predicted based on their effects on lipids as well as on
blood pressure. This appears to be secondary to statins’
effects on proatherosclerotic processes that are common to
many cardiovascular risk factors including hypertension as
well as dyslipidemia. These include the beneficial effects of
statins on inflammation, endothelial function, oxidative
stress, fibrinolytic parameters, and platelet function as well
as on a variety of other effects involved in the atheroscle-
rotic process. CRP, a marker of systemic inflammation, has
received major attention for its role in the development and
maintenance of hypertension as well as of CVD. In addition
to other actions, by increasing ET-1 and IL-6 and reducing
NO production, CRP may change the vascular system
towards a proinflammatory and vasoconstrictive state with
increased arterial stiffness, resulting in hypertension.
Statins have been shown to lower CRP levels in a dose-
dependent fashion and thus may exert part of their
benefits by several parameters involved in the atheroscle-
rotic process.
Conclusions
Prospective randomized trials of MetS patients identified
using NCEP-ATP III criteria that examined benefits on
LDL cholesterol, measures of endothelial function and
inflammation, especially hsCRP, and using such criteria to
determine the contribution to reduction in cardiovascular
events in patients with MetS, would prove very instructive.
Until then, all MetS patients who have a Framingham risk
score of 10% to 20% and elevated hsCRP should be treated
with statins to reduce the burden of subsequent CVD.
Increased CRP levels integrate a myriad of metabolic
abnormalities such as increased adiposity, diabetes, smoking,
end-stage renal disease, hypertension, and MetS. The new
NCEP-ATP III guidelines will now need to consider recom-
mending hsCRP testing to intermediate-risk MetS patients
and those with hypertension and intermediate risk so that we
can better identify candidates at greater risk and reduce
cardiovascular burden in these patients with statin therapy.
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